Biodexa Pharmaceticals Stock Return On Asset
| BDRX Stock | 2.00 0.34 14.53% |
Biodexa Pharmaceticals fundamentals help investors to digest information that contributes to Biodexa Pharmaceticals' financial success or failures. It also enables traders to predict the movement of Biodexa Stock. The fundamental analysis module provides a way to measure Biodexa Pharmaceticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biodexa Pharmaceticals stock.
Biodexa |
Biodexa Pharmaceticals Company Return On Asset Analysis
Biodexa Pharmaceticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Biodexa Pharmaceticals Return On Asset | -0.38 |
Most of Biodexa Pharmaceticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biodexa Pharmaceticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Biodexa Pharmaceticals has a Return On Asset of -0.3752. This is 95.71% lower than that of the Biotechnology sector and 98.41% lower than that of the Health Care industry. The return on asset for all United States stocks is 168.0% higher than that of the company.
Biodexa Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biodexa Pharmaceticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biodexa Pharmaceticals could also be used in its relative valuation, which is a method of valuing Biodexa Pharmaceticals by comparing valuation metrics of similar companies.Biodexa Pharmaceticals is currently under evaluation in return on asset category among its peers.
Biodexa Fundamentals
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (79.31) % | ||||
| Current Valuation | (4.5 M) | ||||
| Shares Outstanding | 668.59 K | ||||
| Shares Owned By Insiders | 8.82 % | ||||
| Shares Owned By Institutions | 29.85 % | ||||
| Number Of Shares Shorted | 46.95 K | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 18.85 X | ||||
| Revenue | 381 K | ||||
| Gross Profit | 145 K | ||||
| EBITDA | (7.16 M) | ||||
| Net Income | (7.08 M) | ||||
| Total Debt | 464 K | ||||
| Book Value Per Share | 24.07 X | ||||
| Cash Flow From Operations | (6.83 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (90.09) X | ||||
| Target Price | 18.71 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 1.56 M | ||||
| Total Asset | 10.54 M | ||||
| Retained Earnings | (144.77 M) | ||||
| Working Capital | 1.46 M | ||||
| Net Asset | 10.54 M |
About Biodexa Pharmaceticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biodexa Pharmaceticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biodexa Pharmaceticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biodexa Pharmaceticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.